Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
|Videos|October 4, 2016
Tara Sanft Discusses Advancements in HER2+ Treatments
Author(s)Tara Sanft, MD
Advertisement
Tara Sanft, MD, of Smilow Cancer Hospital at Yale-New Haven Hospital describes some of the new treatments for patients with HER2+ breast cancer.
Among the drugs available, Sanft explains that pertuzumab used along with trastuzumab and chemotherapy, produces a better chance that the patient will have a pathologic complete response (pCR). Patients who reach pCR go on to have a better prognosis.
Advertisement
Related to this article
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
How AI Could Ease the Cost Crisis in Cancer Care
3
Anktiva Plus BCG: Telling Expected Immune Effects From Red Flags
4
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
5